The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials and integrate them into their clinical practice.
Similar Posts
Decision: Human and veterinary medicines: register of licensed manufacturing sites
The MHRA register of licensed manufacturing sites: manufacturer specials – human (MS) and manufacturer specials authorisation – veterinary (MANSA) only.
Don’t let the heatwave affect your medicines: Three important tips from the MHRA
Essential advice on protecting your medicines during extreme heat and staying safe this summer.
Decision: Advertising Investigations: December 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Guidance: Updates to CIR 520/2012 – Information for UK Marketing Authorisation Holders
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Submission and assessment timetables for innovative medicines applications
Guidance on the deadlines for initial and response submissions.
Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43
Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effects of serious skin reactions.